| Name | Aptamer Group |
|---|---|
| Epic | APTA |
| Isin | GB00BNRRP542 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 0.83p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £22.25 | Debt ratio | n/a |
| Shares in issue | 2,696.98 | Debt-to-equity ratio | n/a |
| P/E ratio | 2.9 | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -152.43 |
| Dividend cover | n/a | EPS growth | -80 |
| Earning per share | 0.14 | 52-week high / low | 0.22p / 1.30p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Aptamer Group |
|---|---|
| Address | Windmill House, Innovation Way, Heslington, York, United Kingdom, YO10 5BR |
| Telephone | +44 (0)1904 217 404 |
| Website | http://aptamergroup.com/ |
| Director | Position |
|---|---|
| Dr Arron Tolley | CEO |
| Mr Andrew Rapson | CFO |
| Mr Timothy J Sykes | Non-Executive Director |
| Dr Adam Hargreaves | Non-Executive Chairman |
| Dr David Harry John Bunka | Chief Technical Officer |
| Assets £ (m) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Reporting date | 30/06/25 | 30/06/24 | 30/06/23 |
| Intangible asssets and goodwill | 0.23 | 0.17 | 0.07 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 1.01 | 1.15 | 1.16 |
| Inventory / work in progress | 0.08 | 0.12 | 0.2 |
| Trade and other receivables | 0.53 | 0.44 | 0.68 |
| Cash and equivalents | 1.06 | 0.87 | 0.23 |
| Other current assets and asset held for resale | 0.15 | 0.19 | 0.47 |
| Total of all assets | 2.83 | 2.77 | 2.75 |
| Liabilities £ (m) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Short term liabilities | 1.18 | 1.28 | 1.64 |
| Long term liabilities | 0.28 | 0.6 | 0.81 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 1.45 | 1.88 | 2.45 |
| Net assets £ (m) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net assets | 1.38 | 0.89 | 0.3 |
| Equity £ (m) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Share capital | 1.99 | 0.47 | 0.07 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -15.05 | -12.94 | -10.07 |
| Share premium account | 13.63 | 12.67 | 9.58 |
| Total equity | 1.38 | 0.89 | 0.3 |
| Income £ (m) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -2.54 | -3.08 | -8.16 |
| Pre-tax profit | -2.57 | -3.14 | -8.3 |